Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration
October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.
VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.
For more information about VARUBI, please access:
https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html
Top resources
National Cancer Prevention Month: Majority View Encouraging Screening as an Act of Love
Americans increasingly view colorectal cancer screening encouragement as an act of love, with new survey data showing rising openness about lifesaving prevention.
Colorectal Cancer Alliance Appoints Alisa Lessing to Board of Directors
Alisa Lessing has joined the Colorectal Cancer Alliance's Board of Directors, bringing extensive governance expertise and a personal commitment to ending colorectal cancer.
New Data Shows Colorectal Cancer is Deadliest Cancer for Adults Under 50
The Colorectal Cancer Alliance (Alliance), the nation’s largest nonprofit dedicated to ending the disease, is calling for urgent action following new evidence from the American Cancer Society published in the Journal of the American Medical Association showing that colorectal cancer is now the leading cause of cancer-related death among men and women under age 50.